FundedIQ
Biotechnology

Pheast Therapeutics: Funding, Investors & Team (Sep 2026)

Pheast Therapeutics is a cancer immunotherapy company focused on developing novel checkpoint therapies to harness the innate immune system in the fight against cancer.

www.pheast.com LinkedIn Palo Alto, United States 11-50 employees
Total raised
$76.0M
Rounds
1
Latest
Series A
Apr 2022

Pheast Therapeutics has raised $76.0M across 1 funding round on record, the most recent a Series A of $76.0M announced in Apr 2022.

That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.

Pheast Therapeutics Company Profile and Key Stats

Total funding raised
$76.0M
across 1 round on record
Funding rounds on record
1
Latest funding round
Series A
$76.0M in Apr 2022
Employees
11-50
reported band
Headquarters
Palo Alto, United States

Latest funding round on record: Apr 2022.

Pheast Therapeutics Funding Rounds

Date
Round
Amount
Series A
$76.0M

Pheast Therapeutics Founders and Leadership Team

Name
Role
Contact
Amira Barkal
Founder

No contact details are on record for this team yet.

Pheast Therapeutics Funding Compared to Other Biotechnology Startups

Segment
Companies
Median round
4,182
$8.0M
29,795
$7.5M
8,378
$15M

Pheast Therapeutics' latest round of $76.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.

Funded Startups Like Pheast Therapeutics in Biotechnology and Palo Alto

Companies Similar to Pheast Therapeutics

Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…

Series B $65.5M

Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…

Seed $7.0M

ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…

Series C $10.0M

EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…

Series A $35.0M

Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…

Convertible Note $3.5M

Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…

Convertible Note $6.8M

XiltriX North America is an information technology company that specializes in monitoring, predictive…

Undisclosed round $3.0M

Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…

Seed $3.1M

Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…

Series D $66.0M

Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…

Series B $92.7M

Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…

Series C $110M

InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…

Series B $77.0M

Pheast Therapeutics Funding FAQs

What does Pheast Therapeutics do?

Pheast Therapeutics is a cancer immunotherapy company focused on developing novel checkpoint therapies to harness the innate immune system in the fight against cancer.

How much funding has Pheast Therapeutics raised?

Pheast Therapeutics has raised $76.0M across 1 round on record. The most recent is a Series A of $76.0M announced in Apr 2022.

When did Pheast Therapeutics last raise funding?

Pheast Therapeutics' most recent funding round on record is a Series A of $76.0M, announced in Apr 2022.

Who founded Pheast Therapeutics?

FundedIQ lists Amira Barkal (Founder) at Pheast Therapeutics.

Where is Pheast Therapeutics headquartered?

Pheast Therapeutics is based in Palo Alto, California, United States.

How many employees does Pheast Therapeutics have?

Pheast Therapeutics is in the 11-50 employee band.

How does Pheast Therapeutics' funding compare to other Biotechnology startups?

Pheast Therapeutics' latest round of $76.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.

About FundedIQ's Pheast Therapeutics Funding Data

FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.

Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Pheast Therapeutics is left off this page rather than filled in.

14-day free trial · Cancel anytime

Know who just raised. Then know who to reach.

Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.

Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.